Slide 1: Q1 FY2023 Financial Results
Q1 FY2023 Financial Results February 1, 2023
Slide 2: Cautionary note regarding forward-looking statements
Cautionary note regarding forward-looking statements Certain of the statements contained in this presentation are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Securit
Slide 3: United in our responsibility to create healthier futures
AmerisourceBergen is united in our responsibility to create healthier futures. AmerisourceBergen creates unparalleled access, efficiency, and reliability for human and animal health as a leading provider of pharmaceutical distribution services and differentiated value-added solutions for upstream an
Slide 4: Overview
Overview Recent highlights Global healthcare leader Fiscal 2023 guidance • Performance driven by • Foundation of leadership in • Updated fiscal 2023 value-creating capital pharmaceutical distribution guidance reflects lower deployment, business • Complementary higher- average diluted share resilienc
Slide 5: Q1 FY2023 financial results: Consolidated results
Q1 FY2023 financial results Consolidated results GAAP Adjusted (non-GAAP)1 Revenue $62.8B $62.8B % Change (Year-over-Year) 5.4% 5.4% Gross profit $2.1B $2.1B % Change 4.2% 5.4% Operating expenses $1.5B $1.4B % Change 6.8% 9.8% Operating income $633M $734M % Change (1.7)% (2.1)% Interest expense, net
Slide 6: U.S. Healthcare Solutions segment
Q1 FY2023 financial results U.S. Healthcare Solutions segment Q1 FY2023 Q1 FY2022 YoY Change Revenue $56.2B $53.0B 6.1% Operating income $572M $569M 0.6% Percentages of revenue Gross profit 2.46% 2.41% Operating expenses 1.45% 1.34% Operating income 1.02% 1.07% ▪ Revenue increase of 6.1% due to over
Slide 7: International Healthcare Solutions segment
Q1 FY2023 financial results International Healthcare Solutions segment Q1 FY2023 Q1 FY2022 YoY Change Revenue, as reported $6.6B $6.6B (0.6)% Revenue, constant currency1 17.7% Operating income, as reported $161M $180M (10.4)% Operating Income, constant currency 1 10.8% Percentages of revenue, as rep
Slide 8: Consolidated FY 2023 guidance
Consolidated FY 2023 guidance Updated guidance reflects lower average diluted share count, updated FX rates, earlier than expected close of PharmaLex, and incrementally lower contributions from COVID-19 treatment distribution As reported Constant As reported Constant currency1 excluding COVID- curre
Slide 9: Segment level FY 2023 guidance
Segment level FY 2023 guidance Updated guidance reflects lower average diluted share count, updated FX rates, earlier than expected close of PharmaLex, and incrementally lower contributions from COVID-19 treatment distribution U.S. Healthcare Solutions As reported Excluding COVID-19 contributions Re
Slide 10: Creating differentiated value for our stakeholders
Creating differentiated value for our stakeholders Our long-term, sustainable growth is supported by investments in our people and culture and commitment to ESG Why we exist Our 5 Strategic Imperatives We are united in our responsibility to create healthier futures Advance core business Enhance capa
Slide 11: Advancing environmental, social, and governance initiatives
Advancing environmental, social, and governance initiatives to create healthier futures around the world ENVIRONMENTAL SOCIAL Adapting to a changing climate Investing in our people and communities • Near-term Science-Based Target validated by • Launched a Global Inclusion Index to measure the Scienc
Slide 12: Appendix
Appendix
Slide 13: Non-GAAP reconciliation
1. Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the latter of which is recorded within Other Loss (Income), Net. 13 Note: For more information related to non-GAAP financial measures, refer to the section titled “Supplement
Slide 14: Non-GAAP reconciliation
1. Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the latter of which is recorded within Other Loss (Income), Net. Note: For more information related to non-GAAP financial measures, refer to the section titled “Supplemental
Slide 15: Supplemental Information Regarding Non-GAAP Financial Measures
Supplemental Information Regarding Non-GAAP Financial Measures To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses the non-GAAP financial measures described below. The non-GAAP financial measures should be viewed in
Slide 16: Supplemental Information Regarding Non-GAAP Financial Measures (Cont.)
Supplemental Information Regarding Non-GAAP Financial Measures (Cont.) • Adjusted income before income taxes: Adjusted income before income taxes is a non-GAAP financial measure that excludes the same items that are described above and excluded from adjusted operating income. In addition, the recove
Slide 17: Supplemental Information Regarding Non-GAAP Financial Measures (Cont.)
Supplemental Information Regarding Non-GAAP Financial Measures (Cont.) • Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments including gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credi
Slide 18: Contact
Contact Bennett S. Murphy Senior Vice President Head of Investor Relations and Treasury bmurphy@amerisourcebergen.com